Common Questions About Recurrent Urinary Tract Infections in Women

JAMES J. ARNOLD, DO; LAURA E. HEHN, MD; and DAVID A. KLEIN, MD, MPH, National Capital Consortium Family Medicine Residency, Fort Belvoir, Virginia

Recurrent urinary tract infections (UTIs) are common in women, including healthy women with normal genitourinary anatomy. Recurrent UTI is typically defined as three or more UTIs within 12 months, or two or more occurrences within six months. The same species that caused previous infections is typically responsible for recurrences. In premenopausal women, sexual intercourse three or more times per week, spermicide use, new or multiple sex partners, and having a UTI before 15 years of age are established risk factors. In postmenopausal women, risk is primarily increased by sequelae of lower estrogen levels. Episodes of recurrent UTI are typically characterized by dysuria and urinary frequency or hesitancy. Findings from the history or physical examination that suggest complicated infection or another disease process warrant additional evaluation. At least one symptomatic episode should be verified by urine culture to confirm the diagnosis and guide treatment. Imaging is rarely warranted. Short courses of antibiotics are as effective as longer courses. Patient-initiated treatment lowers the cost of diagnosis, number of physician visits, and number of symptomatic days compared with physician-initiated treatment. It also reduces antibiotic exposure compared with antibiotic prophylaxis. Antibiotic prophylaxis effectively limits UTI recurrence but increases the risk of antibiotic resistance and adverse effects. Cranberry products may reduce recurrent UTIs in premenopausal women, but are less effective than antibiotic prophylaxis, and data are conflicting. Optimal dosing is unknown. Postmenopausal women with atrophic vaginitis may benefit from topical estrogen therapy. (Am Fam Physician. 2016;93(7):560-569. Copyright © 2016 American Academy of Family Physicians.)

U<br/>

Urinary tract infections (UTIs) are the most common bacterial infection in women of all ages. An estimated 30% to 44% of women will have a second UTI within six months of an initial infection. Healthy women with normal urologic anatomy account for most patients who have recurrent UTIs. Recurrent UTI is typically defined as three or more UTIs in 12 months, or two or more infections in six months. Recurrence is thought to occur by ascent of uropathogens in fecal flora along the urogenital tract and by reemergence of bacteria from intracellular bacterial colonies in uroepithelial cells. In either mechanism, the same species that caused the initial infection is typically the reinfecting agent. Escherichia coli causes approximately 75% of recurrent UTIs; most other infections are caused by Enterococcus faecalis, Proteus mirabilis, Klebsiella, or Staphylococcus saprophyticus. This article addresses common questions about recurrent UTIs in otherwise healthy nonpregnant women.

What Are the Risk Factors for Recurrent UTIs?

Independent risk factors for recurrent UTIs in premenopausal women include sexual intercourse three or more times per week, spermicide use, new or multiple sex partners, and having a UTI before 15 years of age. In postmenopausal women, estrogen deficiency and urinary retention are strong contributors.

EVIDENCE SUMMARY

Frequent intercourse likely causes inoculation of the urethra and bladder by fecal flora, whereas spermicide use disrupts the healthy Lactobacillus flora of the vaginal canal, thereby allowing ascent of uropathogens. In premenopausal women, intercourse three or more times per week triples the risk of UTI. Well-designed case-control studies suggest that body mass index, skipping breakfast, and drinking alcohol increase risk. Postcoital urination seems to
In otherwise healthy postmenopausal women, estrogen deficiency is a risk factor for recurrent UTIs because of changes in *Lactobacillus* flora and vaginal pH. Other risk factors in postmenopausal women include incontinence, a postvoid residual urinary volume exceeding 150 mL, structural abnormalities (e.g., cystocele), type 1 or 2 diabetes mellitus, or a history of more than five UTIs. Activities that increase intra-abdominal pressure (e.g., long-distance walking or traveling) may exacerbate incontinence, cystocele, or postvoid residual urine, and may predispose women who engage in these activities to UTIs.

**Is Susceptibility to Recurrent UTIs Inherited?**

Inherited factors seem to influence a woman's susceptibility to recurrent UTIs. However, such influences are largely nonmodifiable and therefore do not alter clinical recommendations.

**EVIDENCE SUMMARY**

Having a first-degree female relative with a history of five or more UTIs is a risk factor for recurrent UTIs. Specific inheritance patterns, such as nuanced neutrophil receptors and nonsecretor status of blood-type antigens, may decrease the immune system’s ability to clear bacteria or prevent their attachment to uroepithelium. Furthermore, variations in urogenital tract anatomy, including a short urethral-anal distance, may predispose some women to UTIs.

When Is Further Clinical Evaluation Recommended?

A history suggestive of uncomplicated acute cystitis in patients with a previous culture-confirmed UTI is typically sufficient for diagnosis of recurrent infection. Physical examination, laboratory testing, and imaging have limited utility and are not universally recommended.

**EVIDENCE SUMMARY**

Figure 1 presents a suggested approach to the evaluation and management of recurrent UTIs. Uncomplicated acute cystitis, including recurrent episodes, is typically characterized by a combination of dysuria, urinary frequency, and urinary hesitancy. Clinicians should be confident in a patient’s self-diagnosis of recurrent UTI based on symptoms consistent with previous
Evaluation and Management of Recurrent UTI

Nonpregnant woman with history of at least two UTIs in six months or at least three in 12 months, at low risk of complicated infection

Not symptomatic

Symptoms suggest uncomplicated UTI: treat accordingly

Consider verifying normal genitourinary anatomy

Verify that symptoms are similar at each episode, and that at least one episode was confirmed by culture to be caused by a typical uropathogen

Consider:
Voiding after intercourse and avoiding spermicide
Cranberry products (in premenopausal women)
Topical estrogen (in postmenopausal women)
Prophylactic antibiotics

Patient desires prophylactic antibiotics

Infections are temporally related to intercourse

Postcoital antibiotic favored over daily low-dose antibiotic

Patient seeks medical care for future episodes

Infections are not temporally related to intercourse

Daily low-dose antibiotic favored over postcoital antibiotic

Patient seeks medical care for future episodes

Patient declines prophylactic antibiotics

Offer antibiotic prescription for patient-initiated treatment of future episodes

Patient declines

Physician initiates treatment for future episodes with similar symptoms

Patient accepts

Patient initiates treatment for future episodes with similar symptoms

Patient seeks medical care for prolonged, different, or worsening symptoms

Figure 1. Approach to low-risk, nonpregnant women with recurrent urinary tract infections (UTIs).

Information from references 3, and 11 through 17.

culture-confirmed infections. In prospective studies, patient suspicion of UTI is more than 85% accurate in predicting culture-positive infections; this is more accurate than urine dipstick testing. However, additional evaluation and treatment are warranted in patients with fever, nausea, vomiting, acute back pain, previous urogenital surgery, bladder catheterization, vaginal discharge, pelvic pain, or exposure to a sexually transmitted infection, because these may be signs of a complicated infection or another disease process. Pregnancy testing should be considered in premenopausal women. If the patient reports incontinence, overactive bladder, or incomplete bladder emptying,
postvoid residual urinary volume and urodynamic testing may be helpful in guiding treatment.\textsuperscript{14,23} Patients who are candidates for prophylactic or self-initiated treatment should have at least one positive urine culture (at least 10\textsuperscript{2} bacterial colonies per mL of a known urinary pathogen) while symptomatic to confirm concordance of symptoms with a true infection.\textsuperscript{3,5,11,15,17,22} Thereafter, repeat testing during recurrence of typical symptoms may increase cost and inconvenience for the patient, and subsequent benefit is unclear.\textsuperscript{11,12,17,23-25} However, repeat cultures should be obtained to establish resistance patterns in patients who have breakthrough UTIs while receiving prophylactic therapy.\textsuperscript{11,16} Cultures are warranted in patients with persistent UTI symptoms after 48 hours of antibiotic therapy, or with persistent symptomatic bacteriuria after two weeks of culture-directed antibiotic therapy because this may indicate a relapsed infection, which typically occurs because of antibiotic resistance or a persistent nidus of infection.\textsuperscript{3,11,13,18} Patients with persistent symptoms but negative cultures should be evaluated for a noninfectious cause of dysuria, such as interstitial cystitis or bladder cancer.\textsuperscript{3,11}

The usefulness of pelvic examination in women with recurrent UTIs is limited; however, findings that predispose patients to complicated UTIs (e.g., cystocele, urethral diverticulum, fistula) may be detected.\textsuperscript{14,23} Imaging of the upper and lower urologic system with ultrasonography or computed tomography is typically unnecessary and should be guided by the presence of risk factors (Table 1).\textsuperscript{3,12,14,23} The diagnostic yield of cystoscopy suggesting anatomic abnormalities is less than 15%; therefore, routine cystoscopy is unwarranted.\textsuperscript{23,26-28} Cystoscopy in the setting of negative imaging findings is rarely diagnostic; therefore, noninvasive imaging should be completed first.\textsuperscript{23}

**Which Antibiotic Regimens Are Appropriate for Recurrent UTIs?**

*Uncomplicated infections can be treated with a three-day course of trimethoprim/sulfamethoxazole, a five-day course of nitrofurantoin, or a one-day course of fosfomycin (Monurol).\textsuperscript{1,29-32} These regimens are preferred to fluoroquinolones to minimize antibiotic resistance. Beta-lactams are less effective. Recommended regimens are the same for women with diabetes.*

**EVIDENCE SUMMARY**

Patients with recurrent UTIs may be at higher risk of non–E. coli infection compared with those who have isolated acute cystitis.\textsuperscript{33} However, both disease processes are caused by similar pathogens and are treated according to local resistance patterns, patient factors, and drug availability (Table 2).\textsuperscript{3,5,11,12,21,23,28-32,34-36} Compared with longer treatment durations, three-day courses of bactericidal antimicrobials are associated with fewer adverse effects, improved treatment adherence, and similarly low risk of progression to pyelonephritis (less than 1%).\textsuperscript{11,29-31}

Persistent bacteriuria after resolution of clinical symptoms should be considered asymptomatic bacteriuria and should not be further treated in nonpregnant women.\textsuperscript{37,38} Furthermore, treatment of asymptomatic bacteriuria may increase the risk of UTI recurrence by altering normal flora.\textsuperscript{37,38}

**Table 1. Selected Factors That Warrant Further Evaluation in Patients with Recurrent Urinary Tract Infections**

<table>
<thead>
<tr>
<th>Factor</th>
<th>Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hematuria (macroscopic or microscopic) persisting after clearance of infection, noted by resolution of symptoms or a negative urine culture</td>
<td>*—Consider further workup if urine culture shows presence of struvite stone–producing (urea-splitting) organisms (e.g., Proteus, Klebsiella, Pseudomonas). Information from references 3, 12, 14, and 23.</td>
</tr>
<tr>
<td>History of urinary tract malignancy</td>
<td></td>
</tr>
<tr>
<td>History of urinary tract surgery or trauma, or diverticular disease</td>
<td></td>
</tr>
<tr>
<td>History or presence of calculi*</td>
<td></td>
</tr>
<tr>
<td>Multidrug-resistant organism</td>
<td></td>
</tr>
<tr>
<td>Persistent symptoms and bacteriuria despite two weeks of culture-directed therapy</td>
<td></td>
</tr>
<tr>
<td>Pneumaturia or fecaluria</td>
<td></td>
</tr>
<tr>
<td>Presence of anaerobic organisms (with the exception of facultative anaerobes [e.g., <em>Escherichia coli</em>, <em>Staphylococcus</em> species])</td>
<td></td>
</tr>
<tr>
<td>Repeat episodes of pyelonephritis or treatment-resistant pyelonephritis</td>
<td></td>
</tr>
<tr>
<td>Symptoms of urinary obstruction</td>
<td></td>
</tr>
<tr>
<td>Voiding dysfunction (e.g., elevated postvoid residual volume, incontinence)</td>
<td></td>
</tr>
</tbody>
</table>
Recurrent UTI

Table 2. Treatment Regimens for Uncomplicated Acute Cystitis and Recurrent Urinary Tract Infections

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Dosage</th>
<th>Effectiveness (%)</th>
<th>Resistance rate (%)*</th>
<th>Cautions and contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First-line agents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fosfomycin (Monurol)</td>
<td>3-g packet one time</td>
<td>91</td>
<td>Up to 0.6</td>
<td>Hypersensitivity to fosfomycin, suspected pyelonephritis</td>
</tr>
<tr>
<td>Nitrofurantoin</td>
<td>100 mg two times per day for five days</td>
<td>93</td>
<td>Up to 1.6</td>
<td>Glomerular filtration rate less than 40 to 60 mL per minute, history of cholestatic jaundice or hepatic dysfunction with previous use, pregnancy (greater than 38 weeks’ gestation), pulmonary or hepatic fibrosis, suspected pyelonephritis; use with caution in patients with G6PD deficiency</td>
</tr>
<tr>
<td>Trimethoprim/</td>
<td>160/800 mg two times per day for three days</td>
<td>93</td>
<td>Up to 24.2</td>
<td>History of drug-induced thrombocytopenia or other hematologic disorder, local resistance rates greater than 20%, pregnancy, sulfa allergy, use in previous three to six months; use with caution in patients with hepatic or renal impairment, porphyria, or G6PD deficiency</td>
</tr>
<tr>
<td>sulfamethoxazole</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Second-line agents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluoroquinolones (e.g., ciprofloxacin, levofloxacin [Levaquin])</td>
<td>Ciprofloxacin: 250 mg two times per day for three days Levofoxacin: 250 to 500 mg per day for three days</td>
<td>90</td>
<td>Ciprofloxacin: up to 17 Levofoxacin: up to 6</td>
<td>Concurrent use with medications that prolong QT interval, hypokalemia, hypomagnesemia, local resistance rates greater than 10%, myasthenia gravis, pregnancy; use with caution in patients with renal impairment</td>
</tr>
<tr>
<td><strong>Alternative agents if first- and second-line agents are contraindicated</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beta-lactams (e.g., amoxicillin/clavulanate [Augmentin], cefaclor, cefdinir, cefpodoxime, cephalexin [Keflex])</td>
<td>Amoxicillin/clavulanate: 500/125 mg two times per day for three days Cefaclor: 250 mg three times per day for five days Cefdinir: 300 mg two times per day for five days Cefpodoxime: 100 mg two times per day for three days Cephalexin: 500 mg two times per day for seven days</td>
<td>89</td>
<td>Varies by medication</td>
<td>Cephalosporin or penicillin allergy, history of cholestatic jaundice with previous use; use with caution in patients with renal or hepatic impairment, history of infectious colitis, or active mononucleosis; use cephalexin with caution in patients with elevated international normalized ratios</td>
</tr>
</tbody>
</table>

ESBL = extended-spectrum beta-lactamase; G6PD = glucose-6-phosphate dehydrogenase; NA = not available.

*—Resistance information is based on averages from one large 2010 multicenter analysis of 12 million outpatient cultures obtained throughout the United States.† Resistance information is difficult to ascertain because most laboratories do not routinely test its susceptibility. However, one international multicenter study found resistance rates of 0.6%,‡ and its effectiveness was demonstrated in a 2010 meta-analysis.§ Local resistance rates may vary.

†—Estimated retail cost for one course of therapy based on information obtained at http://www.goodrx.com (accessed July 21, 2015). Cost for generic listed first; brand name in parentheses, when available.

Information from references 1, 3, 5, 11, 12, 21, 23, 29 through 32, and 34 through 36.
### Table 2. Treatment Regimens for Uncomplicated Acute Cystitis and Recurrent Urinary Tract Infections

<table>
<thead>
<tr>
<th>Adverse effects</th>
<th>Cost†</th>
<th>U.S. Food and Drug Administration pregnancy category</th>
<th>Comments</th>
<th>Infectious Diseases Society of America recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhea, headache, nausea, vaginitis</td>
<td>NA ($69)</td>
<td>B</td>
<td>Minimal change in gut flora; effective against methicillin-resistant <em>Staphylococcus aureus</em>, ESBL-producing organisms, <em>Enterococcus faecalis</em>, vancomycin-resistant <em>Enterococcus</em></td>
<td>Single dose is appropriate for acute cystitis despite concerns about effectiveness</td>
</tr>
<tr>
<td>Flatus, headache, hemolytic anemia, nausea, neuropathy; risk of pulmonary and hepatic fibrosis with long-term use</td>
<td>$19 (NA)</td>
<td>B</td>
<td>Minimal change in gut flora; should be taken with meals; may turn urine orange; effective against <em>E. faecalis</em>, <em>S. aureus</em>, and <em>Staphylococcus saprophyticus</em></td>
<td>Five-day course is as effective as three-day course of trimethoprim/sulfamethoxazole for treatment of acute cystitis</td>
</tr>
<tr>
<td>Bone marrow suppression, electrolyte abnormalities, hepatotoxicity, nausea, nephrotoxicity, photosensitivity, rash, Stevens-Johnson syndrome</td>
<td>$4 (NA)</td>
<td>D</td>
<td>Alters gut flora</td>
<td>Three-day course is appropriate if local resistance rates do not exceed 20%</td>
</tr>
<tr>
<td>Diarrhea, drowsiness, headache, insomnia, nausea, QT interval prolongation, tendon rupture</td>
<td>Ciprofloxacin: $4 (NA)</td>
<td>C</td>
<td>Alters gut flora; ciprofloxacin is preferred over other fluoroquinolones; limit use to patients with pyelonephritis or resistant cystitis</td>
<td>Three-day course is highly effective for treatment of cystitis; reserve for treatment of more severe conditions (e.g., pyelonephritis)</td>
</tr>
<tr>
<td>Diarrhea (including <em>Clostridium difficile</em> colitis), headache, hepatotoxicity, nausea, rash, vaginitis</td>
<td>Amoxicillin/clavulanate: $10 ($300) Cefaclor: $28 (NA) Cefdinir: $19 (NA) Cefpodoxime: $21 (NA) Cephalexin: $4 ($130)</td>
<td>B</td>
<td>Alters gut flora; use with caution because of increasing prevalence of ESBL-producing <em>Escherichia coli</em></td>
<td>Courses of three to seven days are appropriate if other agents cannot be used; fewer supporting data for cephalexin; high resistance rates should preclude use of amoxicillin</td>
</tr>
</tbody>
</table>

† Resistance rates: United States. ESBL = beta-lactamase. **Meta-analysis** of local resistance rates reported to the Centers for Disease Control and Prevention.

**Table Legend**
- **Cost†**: Estimated retail cost for one course of therapy based on information obtained at www.goodrx.com.
- **Adverse effects**: See text for full listing of adverse effects.
- **Cautions and contraindications**: See text for full listing of cautions and contraindications.
- **Dosage**: See text for full listing of dosage instructions.
- **Comments**: See text for full listing of comments.
- **U.S. Food and Drug Administration pregnancy category**: See text for full listing of pregnancy categories.
Recurrent UTI

Although UTIs in women with diabetes have historically been classified as complicated, new limited data suggest that causative pathogens and resistance rates are comparable to those of UTIs in women without diabetes. Two recent systematic reviews suggest that UTIs in women with diabetes should be treated in the same manner as those in women without diabetes unless risk factors for functionally or anatomically altered voiding are present.

What Are the Benefits of Patient-Initiated Treatment?

Patient-initiated treatment lowers the cost of diagnosis, physician visits, and symptomatic days compared with physician-initiated treatment, and reduces antibiotic exposure compared with antibiotic prophylaxis.

EVIDENCE SUMMARY

No reduction in UTI episodes is achieved when patients initiate treatment. However, compared with prophylactic strategies or physician-initiated treatment, this approach seems to minimize the physiologic and financial cost of frequent antibiotic use, cost of diagnosis, number of physician visits, and number of symptomatic days, by limiting doses to symptomatic events.

Which Prophylactic Regimens Are Recommended?

Continuous daily and postcoital low-dose antibiotic prophylactic regimens decrease recurrence of symptomatic UTIs by approximately 95%, although patients may revert to preprophylaxis recurrence rates once prophylaxis is discontinued.

EVIDENCE SUMMARY

A large meta-analysis conducted in 2004 demonstrated that clinical recurrence of UTI is greatly reduced during antibiotic prophylaxis (relative risk [RR] = 0.15; 95% confidence interval [CI], 0.08 to 0.28; number needed to treat = 2). However, once prophylaxis was discontinued, patients reverted to pretreatment frequency of UTI.

Clinicians should be mindful of local resistance patterns, patient factors, and drug availability when selecting the antimicrobial agent. Regimens have similar effectiveness, and all may lead to gastrointestinal upset, vaginal candidiasis, and rash.

Compared with daily prophylaxis, postcoital prophylaxis reduces the total amount of antibiotics used without compromising effectiveness. This approach may be appropriate for patients with intercourse-associated UTIs, and may further limit antibiotic exposure in patients who have infrequent intercourse.

Data suggest that intracellular bacterial communities coalesce as early as three hours after inoculation into the bladder; accordingly, antibiotics taken within two hours of intercourse may be optimal to prevent UTIs.

The optimal duration of antibiotic prophylaxis is unknown. Based on consensus opinion and limited data, an initial six- to

<table>
<thead>
<tr>
<th>Medication</th>
<th>Continuous dosage</th>
<th>Postcoital dose</th>
<th>Cost*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Commonly used first-line agents</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nitrofurantoin</td>
<td>50 to 100 mg per day</td>
<td>100 mg</td>
<td>$29 to $45 (NA)</td>
</tr>
<tr>
<td>Trimethoprim/sulfamethoxazole</td>
<td>40/200 mg (one-half of an 80/400-mg tablet) per day or 40/200 mg three times per week (alternative)</td>
<td>40/200 mg or 80/400 mg</td>
<td>$4 to $6 (NA)</td>
</tr>
<tr>
<td><strong>Occasionally used first-line agents</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cefaclor</td>
<td>250 mg per day</td>
<td>—</td>
<td>$47 (NA)</td>
</tr>
<tr>
<td>Cephalexin (Keflex)</td>
<td>125 to 250 mg per day</td>
<td>250 mg</td>
<td>$5 to $10 ($47 to $94)</td>
</tr>
<tr>
<td>Trimethoprim</td>
<td>100 mg per day</td>
<td>—</td>
<td>$13 (NA)</td>
</tr>
<tr>
<td><strong>Agents not commonly used for prophylaxis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>125 mg per day</td>
<td>125 mg</td>
<td>$9 (NA)</td>
</tr>
<tr>
<td>Fosfomycin (Monurol)</td>
<td>One 3-g packet every 10 days</td>
<td>—</td>
<td>NA ($195 for three packets)</td>
</tr>
<tr>
<td>Ofloxacin</td>
<td>—</td>
<td>100 mg</td>
<td>$17 (NA)</td>
</tr>
</tbody>
</table>

**NOTE:** All regimens have demonstrated an expected frequency of less than one urinary tract infection per year, compared with 0.8 to 3.6 per year with placebo.

NA = not available.

*Estimated retail price for 30 doses (unless noted otherwise) based on information obtained at http://www.goodrx.com (accessed July 21, 2015). Cost for generic listed first; brand name in parentheses, when available.

Information from references 3, 12, 14, 16, and 23.
12-month course should be offered. Small studies have shown effectiveness for up to five years, although long-term adverse effects such as antibiotic resistance and reversible pulmonary fibrosis from several years of nitrofurantoin use have been reported. Common dosing options for antibiotic prophylaxis are listed in Table 3.

Are There Alternative Treatment Strategies to Limit Antibiotic Use?

A short trial of an analgesic or anti-inflammatory medication for UTI symptoms can limit antibiotic use in willing patients when follow-up is assured. Delaying antibiotic treatment for urinary test results in patients with typical UTI symptoms is not recommended. Prophylaxis with a cranberry product in premenopausal women or topical estrogen therapy in postmenopausal women may limit UTI recurrences and thereby limit antibiotic use, although data about cranberry use are conflicting.

EVIDENCE SUMMARY

A 2009 meta-analysis suggested that symptomatic treatment alone, consisting of a one- to two-day course of a nonsteroidal anti-inflammatory drug (NSAID), is an option in patients with appropriate follow-up because up to one-third of infections resolve spontaneously within one week, with no difference in rates of progression to pyelonephritis. However, a recent small study showed a 60% decrease in antibiotic use but a slightly increased risk of pyelonephritis in patients who received ibuprofen. No recent or conclusive data exist to support the use of urinary tract analgesics such as phenazopyridine as single-agent treatment for UTI. However, they are generally low-risk medications and may provide analgesic alternatives to NSAIDs. Nonetheless, immediate antimicrobial therapy remains the quickest and most effective way to relieve symptoms and provides the best clinical outcomes.

Delaying antibiotic treatment while awaiting urine dipstick or culture results can limit antibiotic use. However, compared with treatment based on self-diagnosis, this strategy is not preferred because it may increase the number of symptomatic days and cost of diagnosis.

Cranberries contain proanthocyanidins, which may prevent adherence of E. coli to uroepithelial cells. Data are conflicting about the effectiveness of cranberry products for preventing recurrent UTI in premenopausal women. A 2012 meta-analysis demonstrated a decrease in UTI rates in women who received daily cranberry tablets (RR = 0.53; 95% CI, 0.33 to 0.83). However, a 2012 Cochrane review found insufficient evidence to recommend routine use of cranberry products for prophylaxis. They are generally a low-risk intervention and may prove to be another means to reduce UTI episodes and antibiotic use. Appropriate dosing and formulation of cranberry products have not been determined. Dosages of 36 to 72 mg per day are being tested in an ongoing clinical trial. Cranberry tablets seem to cause less gastroesophageal reflux and nausea than cranberry juice.

In postmenopausal women, treatment of atrophic vaginitis with topical estrogen formulations may decrease rates of UTI recurrence through effects on vaginal flora. In a 2008 Cochrane review, women treated with topical estrogen had a 50% reduction in UTI recurrence. Oral estrogens are less effective and confer risks associated with systemic hormone replacement, and should not be used for this purpose.

Evidence for intravaginal and oral Lactobacillus probiotics, oral D-mannose, acupuncture, and immunoprophylactic regimens is sparse and conflicting, and further study is warranted.

Data Sources: A PubMed search was completed using the MeSH function with the key phrase recurrent urinary tract infections combined with at least one of the following terms: women, non-pregnant, pre-menopausal and post-menopausal. The search included meta-analyses, randomized controlled trials, clinical trials, and reviews. Also searched were Essential Evidence Plus, the Cochrane Database of Systematic Reviews, the U.S. Preventive Services Task Force website, and relevant recommendations from the Infectious Diseases Society of America and the European Society of Clinical Microbiology and Infectious Diseases. Search dates: October 1, 2014, to February 14, 2016.
Recurrent UTI

The authors thank Margaret Freiberg for her assistance in the preparation of the manuscript.

The opinions and assertions contained herein are the personal views of the authors and are not to be construed as official or as reflecting the views of the U. S. armed services or their medical departments.

The Authors

JAMES J. ARNOLD, DO, FAAFP, is an associate program director at the National Capital Consortium Family Medicine Residency in Fort Belvoir, Va., and an assistant professor of family medicine at the Uniformed Services University of the Health Sciences, Bethesda, Md.

LAURA E. HEHN, MD, is a third-year family medicine resident at the National Capital Consortium Family Medicine Residency.

DAVID A. KLEIN, MD, MPH, FAAFP, is a faculty member at the National Capital Consortium Family Medicine Residency and an assistant professor of family medicine and pediatrics at the Uniformed Services University of the Health Sciences.

Address correspondence to James J. Arnold, DO, FAAFP, Fort Belvoir Community Hospital, 9300 DeWitt Loop, Fort Belvoir, VA 22060 (e-mail: james.j.arnold3@us.af.mil). Reprints are not available from the authors.

REFERENCES


Recurrent UTI